Fri.Nov 10, 2023

article thumbnail

How pharmacy deserts are putting the health of Black and Latino Americans at risk

STAT

Pharmacies were once abundant in the South Side of Chicago. Now, residents living in the majority Black neighborhood often find themselves with few options when it’s time to get a prescription refilled or stock up on cold medicine. Ladell Johnson, a longtime resident of the South Side, drives half an hour from her house to the downtown area every time she needs to pick up her prescription.

363
363
article thumbnail

SAEM Clinical Images Series: Man with a Recurrent Rash

ALiEM - Pharm Pearls

A 33-year-old male presented to the emergency department with a diffuse pruritic rash that appeared several days after starting Trimethoprim/Sulfamethoxazole (TMP-SMX) for a dental infection. Initially beginning on the torso and low back, the rash spread to the palms, soles, and genitalia. Progression stopped after discontinuing TMP-SMX. He conveyed a remote history of a similar rash following use of an unknown medication, and noted that several of the current lesions arose at the same location

161
161
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

U.K. recommendation could lead to world’s first use of meningitis vaccine to curb gonorrhea

STAT

An expert panel that advises the United Kingdom on vaccine policy has recommended using a meningitis B vaccine to try to bring down spiking rates of gonorrhea. If adopted, the U.K. would be the first country to use the meningitis B vaccine for this purpose. The Joint Committee on Vaccination and Immunization released a report Friday saying that targeted use of a meningitis B vaccine — GSK’s Bexsero — in people at high risk of contracting gonorrhea should reduce the inci

Vaccines 357
article thumbnail

100th patient joins ChariotMS trial for multiple sclerosis

Pharma Times

The trial is testing whether Mavenclad could benefit upper limb movement in MS patients - News - PharmaTimes

160
160
article thumbnail

Navigating Payroll Compliance: Future-Proofing Payroll in an Evolving Regulatory Landscape

Speaker: Jennifer Hill

Payroll compliance is a cornerstone of business success, yet for small and midsize businesses, it’s becoming increasingly challenging to navigate the ever-evolving landscape of federal, state, and local regulations. Mistakes can lead to costly penalties and operational disruptions, making it essential to adopt advanced solutions that ensure accuracy and efficiency.

article thumbnail

Opinion: The end of affirmative action means it’s time to revise pre-med requirements

STAT

Luz (not her real name) could be a great doctor. A Latina student from Arizona, she graduated at the top of her high school class and has always aspired to give back to her community. But ultimately, she decided against medical school for one reason: chemistry. It’s not that she isn’t smart enough for chemistry — far from it. She just hates it, finding it dull and unrewarding.

More Trending

article thumbnail

STAT+: What Amazon Prime’s new One Medical offering reveals about the future of health care

STAT

Amazon Prime members have a new offer in addition to the usual delivery and streaming services: Access to One Medical, the Amazon-owned primary care company. Members have the option, announced Wednesday, to pay an additional $9 per month, or $99 per year, for One Medical’s telehealth services and in-office appointments at a discount of about half its typical $199 yearly cost.

294
294
article thumbnail

5 of the best paid biopharma CEOs

PharmaVoice

As revenue growth remained high last year, so did biopharma CEO pay in the U.S.

130
130
article thumbnail

STAT+: Medicare’s new pay boost for primary care is angering specialists

STAT

WASHINGTON — Doctors are staring down a cut to their Medicare pay next year, and while the news has united them in outrage, it’s also turned one specialty against another. Medicare officials last week announced its major annual update to the way the program pays physicians. Along with other changes, it includes a policy that will boost payments to specialties that rely on evaluating and managing patients, as opposed to those that focus on procedures.

278
278
article thumbnail

Bayer pledges up to $1.5bn for Recursion oncology alliance

pharmaphorum

Bayer pledges up to $1.5bn for Recursion oncology alliance Phil.

116
116
article thumbnail

From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

article thumbnail

STAT+: EU regulator recommends expanding diabetes drug Mounjaro’s approval to include obesity

STAT

LONDON — Two days after similar decisions in the U.S. and U.K. , regulators in Europe on Friday recommended that the approval of Eli Lilly’s diabetes drug Mounjaro be widened to include obesity.   The ruling from a committee of the European Medicines Agency now goes to the European Commission, which makes the final decision but almost always follows the EMA’s guidance.

Diabetes 252
article thumbnail

CAR-T biotech Cargo Therapeutics prices $281M IPO

BioPharma Dive

Cargo Therapeutics is the seventh oncology biotech to successfully price an IPO this year.

115
115
article thumbnail

STAT+: Up and down the ladder: The latest comings and goings

STAT

Hired someone new and exciting? Promoted a rising star? Finally solved that hard-to-fill spot? Share the news with us, and we’ll share it with others.   That’s right.  Send us your changes, and we’ll find a home for them. Don’t be shy. Everyone wants to know who is coming and going. And here is our regular feature in which we highlight a different person each week.

204
204
article thumbnail

Novo Nordisk sets aside $6bn to boost production capacity

pharmaphorum

Novo Nordisk sets aside $6bn to boost production capacity Phil.

111
111
article thumbnail

Why Every Small Business Needs an HCM Solution: A Comprehensive Guide

Managing HR tasks like payroll, compliance, and employee data can overwhelm small businesses. That’s where a Human Capital Management (HCM) solution comes in. Our eBook, Why Every Small Business Needs an HCM Solution: A Comprehensive Guide , shows how an HCM system automates tedious processes, ensuring your business stays compliant and efficient. You’ll learn how to simplify payroll, eliminate costly errors, and empower your employees with self-service tools.

article thumbnail

New method could replace microbiology CFU assay

European Pharmaceutical Review

US researchers have developed the Geometric Viability Assay (GVA), which has been shown to be a fast, cheap and sustainable method for counting microorganisms. Since it is 36 times faster than conventional methods, uses 15 times less plastic, and is low cost, Geometric Viability Assay could “replace existing viability assays and enable viability measurements at previously impractical scales”, the paper noted.

111
111
article thumbnail

Takeda gets okay in US for rare blood disorder drug

pharmaphorum

Takeda gets okay in US for rare blood disorder drug Phil.

111
111
article thumbnail

Novo Nordisk plans multi-billion Denmark manufacturing expansion

European Pharmaceutical Review

Novo Nordisk has announced plans to invest over 42 billion Danish kroner (nearly £5 billion) starting in 2023, to expand its manufacturing facilities in Kalundborg, Denmark. According to the pharma company , the financing will add to global capacity: from manufacturing of active pharmaceutical ingredients (API) through to packaging. Most of the investment will be focused on API capacity.

Packaging 111
article thumbnail

Bayer and Recursion focus research collaboration on oncology

World Pharma News

Bayer and US-based Recursion Pharmaceuticals, Inc., a clinical stage TechBio company decoding biology to industrialize drug discovery, announced that they have updated the focus of their research collaboration to precision oncology. The oncology-focused collaboration will leverage Bayer's small molecule compound library and expertise in biology and medicinal chemistry as well as Recursion’s purpose-built artificial intelligence-guided drug discovery platform.

article thumbnail

Best Practices to Streamline Compensation Management: A Foundation for Growth

Speaker: Joe Sharpe and James Carlson

Payroll optimization can be one of the most time-consuming and complex factors of small business management. Yet, organizations that crack the code on streamlining employee compensation often discover innovative avenues for growth. With the right strategies in place, outsourcing and streamlining payroll processes can result in substantial time and resource savings.

article thumbnail

Hub and spoke unlikely to solve sector’s problems, says HSCC chair

The Pharmacist

Former pharmacy minister and chair of the health and social care committee (HSCC) Steve Brine has said he ‘doubts very much’ that changes to hub and spoke legislation is the answer to problems faced by independent community pharmacies. At the Sigma Pharmaceuticals UK conference last weekend, Mr Brine described the government’s silence on hub and […] The post Hub and spoke unlikely to solve sector’s problems, says HSCC chair appeared first on The Pharmacist.

article thumbnail

First chikungunya vaccine approved by FDA

pharmaphorum

First chikungunya vaccine approved by FDA Phil.

Vaccines 107
article thumbnail

6 Root Causes Behind Leaky Gut and Autoimmunity

The Thyroid Pharmacist

I often get messages from people with Hashimoto’s and other autoimmune diseases, that say: “Thanks for your efforts, but I’ve already tried everything. I have cut out gluten, dairy, and soy from my diet, and still have Hashimoto’s. How can your work help me?” While changing your diet is an incredibly important first step that will greatly help many of you, if you do not see a complete remission of your symptoms within three to six months, I encourage you to dig deeper.

Immunity 105
article thumbnail

FDA approves Takeda’s Adzynma for rare blood clotting disorder

Pharmaceutical Technology

The US FDA has granted approval for Takeda’s Adzynma for congenital thrombotic thrombocytopenic purpura, a rare blood clotting disorder.

105
105
article thumbnail

Enhance Healthcare Efficiency With Top Payroll & HCM Services

Running a healthcare facility requires precision and care, not just for patients but also for your staff. Our guide, "A Buyer’s Guide to Payroll & HCM Services," helps healthcare providers choose the best provider. Efficient payroll management ensures timely, accurate payments, critical for maintaining staff morale and trust. Compliance support helps navigate complex healthcare regulations and avoid costly fines.

article thumbnail

D3XTRA Vitamin: Understanding the Importance of Vitamin D

Welltopia Pharmacy

D3XTRA Vitamin: Understanding the Importance of Vitamin D 1.

104
104
article thumbnail

AstraZeneca posts 16% drop in Q3 2023 profit after tax

Pharmaceutical Technology

AstraZeneca has posted a profit after tax of $1.37bn for Q3 2023 versus $1.64bn in the same quarter of the previous year, a decline of 16%.

98
article thumbnail

QA/QC & Microbiology In-Depth Focus 2023

European Pharmaceutical Review

Bioburden and sterility testing: how to conserve gene therapy product Kathy Zagaroli, Senior Director of Quality Control at Kiniksa Pharmaceuticals, and Tom Bujold, Senior Director of Quality Control at REGENXBIO, discuss the challenges of bioburden and sterility testing for gene therapies and why industry must come together to drive increased harmonisation.

98
article thumbnail

Four Trends That Are Shaping the Future of Market Access

Drug Channels

Today’s guest post comes from James Pisano, Partner, Market Access at The Dedham Group and Dinesh Kabaleeswaran, SVP of Insights & Advisory Teams at MMIT. James and Dinesh offer four trends that they predict will shape medication access in the coming years. Click here to learn about consulting services from MMIT and its sister company The Dedham Group.

97
article thumbnail

Position Your Pharmacy for Expansion

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

article thumbnail

Formulation In-Depth Focus 2023

European Pharmaceutical Review

Exploring the complex pathway of paediatric drug development The formulation development of paediatric medications poses unique challenges compared to that of adult medications. Tom Hegarty, Head of Technical Operations for Almac Pharma Services, delves into some of the key considerations when looking to develop child-friendly formulations. Definitive screening design to accelerate process characterisation Mourad Mellal, Director of Statistics, Product Development at Catalent, elucidates the rol

article thumbnail

Sosei Heptares and Kallyope collaboration milestone with first GPCR target

Outsourcing Pharma

The first scientific milestone stemming from a collaboration between Sosei Heptares and Kallyope that was announced last year (2022) has been reached.

80
article thumbnail

BYOOVIZ® (Ranibizumab-Nuna) Granted Interchangeable Status

Big Molecule Watch

Recently, Biogen and Samsung Bioepis’s ranibizumab biosimilar (BYOOVIZ) was granted interchangeable status by the U.S. Food and Drug Administration. BYOOVIZ was deemed interchangeable to Genentech’s LUCENTIS for the treatment of neovascular (wet) age-related macular degeneration, macular edema following retinal vein occlusion, and myopic choroidal neovascularization.